Open label study of ONTAK (denileukin diftitox, DAB389 IL-2) to estimate response in cutaneous T-cell lymphoma (CTCL) according to CD25 status.
Phase of Trial: Phase III
Latest Information Update: 16 Apr 2012
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Therapeutic Use
- Sponsors Ligand Pharmaceuticals
- 16 Apr 2012 Company (Ligand Pharmaceuticals) added and additional lead trial centre identified as reported by ClinicalTrials.gov.
- 05 Aug 2011 Actual end date (Sep 2006) added as reported by ClinicalTrials.gov.
- 05 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.